PP01.58 Real-world Outcomes in Patients With EGFR Wildtype Non-squamous Locally Advanced/Metastatic NSCLC Receiving Second- or Third-Line Docetaxel: Pooled Analysis From LUMINATE-101

IF 21 1区医学 Q1 ONCOLOGY

Journal of Thoracic Oncology Pub Date : 2024-07-01 DOI:10.1016/j.jtho.2024.05.293

Nicolas Girard , Qingqing Xu , D. Ross Camidge , Shobhit Baijal , Sudeep Karve , Sophia Ng , Rajesh Kamalakar , Christine Ratajczak , Allison Allen , Shun Lu

引用次数: 0

查看原文本刊更多论文

PP01.58 接受二线或三线多西他赛治疗的表皮生长因子受体野生型非鳞癌局部晚期/转移性 NSCLC 患者的真实世界结果：来自 LUMINATE-101 的汇总分析

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Thoracic Oncology 医学-呼吸系统

CiteScore

36.00

自引率

3.90%

发文量

1406

审稿时长

13 days

期刊介绍： Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.